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Abstract
Background: Impaired functional status attenuates the relationship of systolic blood pressure (SBP) with mortality in older adults but has not 
been studied in middle-aged populations.
Method: Among 10,264 stroke-free Atherosclerosis Risk in Communities participants (mean age 62.8 [5.7] years; 6,349 [62%] younger 
[<65 years]; 5,148 [50%] men; 2,664 [26%] Black), function was defined as good function (GF) for those self-reporting no difficulty performing 
functional tasks and basic or instrumental tasks of daily living; all others were defined as impaired function (IF). SBP categories were normal 
(<120 mmHg), prehypertension (120–139 mmHg), and hypertension (≥140 mmHg). Mortality risk associated with SBP was estimated using 
adjusted Cox proportional hazard models with a triple interaction between age, functional status, and SBP.
Results: Mean follow-up was 12.9 years with 2,863 (28%) deaths. Among younger participants, 3,017 (48%) had IF; 2,279 of 3,915 (58%) 
older participants had IF. Prehypertension (hazard ratio [HR] = 1.48 [1.03, 2.15] p = .04) and hypertension (HR = 1.97 [1.29, 3.03] p = .002) were 
associated with mortality in younger GF and older (≥65 years) GF participants (prehypertension HR = 1.21 [1.06, 1.37] p = .005; hypertension 
HR = 1.47 [1.36, 1.59] p < .001). Among IF participants, prehypertension was not associated with mortality in younger participants (HR = 0.99 
[0.85, 1.15] p = .93) and was protective in older participants (HR = 0.87 [0.85, 0.90] p < .001). Hypertension was associated with mortality in 
younger IF participants (HR = 1.54 [1.30, 1.82] p < .001) but not in older IF participants (HR = 0.99 [0.87, 1.14] p = .93).
Conclusions: Compared with younger and well-functioning persons, the additional contribution of blood pressure to mortality is much lower 
with older age and impaired function, particularly if both are present. Functional status and age could potentially inform optimal blood pressure 
targets.
Keywords: Blood pressure—Mortality—Middle aged—Functional status
The association between blood pressure (BP) and mortality in older 
adults remains controversial, with several studies reporting U-shaped 
relationships representing higher mortality risk among those with 
the lowest and highest BP, particularly among the oldest old (1–4). 
The Eighth Joint National Commission (JNC) hypertension (HTN) 
guidelines (5) sparked controversy (6,7) with recommendations to 
90 Journals of Gerontology: MEDICAL SCIENCES, 2017, Vol. 72, No. 1
raise the target systolic BP (SBP) for initiating and control of HTN 
to 150 mmHg in persons 60 years or older without diabetes or kid-
ney disease. The debate over BP control is not new (8,9), despite 
randomized controlled trials demonstrating benefits of lowering BP 
in hypertensive persons older than 60 years (10–12) and in hyper-
tensive persons 80 years and older in the Hypertension in the Very 
Elderly Trial (HYVET) (13). Opposing arguments cite attenuated 
benefit or even increased mortality among older participants in treat-
ment arms of clinical trials of HTN (10–12,14,15), associations of 
higher BP with better outcomes among older adults in cohort studies 
(16,17), and lack of generalizability to persons frequently encoun-
tered in clinical practice including those with multiple comorbidities, 
physical or cognitive disabilities, frailty, and those in nursing homes 
or assisted living facilities (8,18,19).
Age, however, may not be the best predictor of clinical risk. 
Measures of functional status are important vital signs of health in 
older adults (20), are associated with mortality and other adverse 
outcomes, and modify life expectancy (21,22) in older adults. Recent 
reports demonstrate that self-reported (fast, medium, and slow) (23) 
and objectively measured walking speed (24) modifies the relation-
ship of BP with mortality in older adults, with no association observed 
between higher BP and mortality among slow walkers but a signifi-
cantly higher risk of mortality among faster walkers with higher BP. 
These findings suggest that functional measures may be informative 
for understanding risks and benefits associated with HTN and HTN 
treatment in older persons. If functional measures provide informa-
tion on mortality risk apart from age alone, functional status may 
also modify the relationship of BP to mortality in younger as well as 
older persons. The effect of functional status on the relationship of 
BP to mortality has not been examined in middle-aged populations.
The aim of this study was to examine the effects of age and func-
tional status on the relationship of SBP to all-cause mortality in a 
middle-aged and older biracial population.
Method
Population
The Atherosclerosis Risk in Communities (ARIC) is a prospective 
study of a community-dwelling cohort of men and women at four 
sites in the United States (Forsyth County, NC; Jackson, MS; sub-
urbs of Minneapolis, MN; and Washington County, MD) designed 
to investigate the natural history of atherosclerosis as previously 
reported (25). At baseline (1987–1989), 15,792 participants were 
sampled; participants were predominantly White in MD and MN. 
All participants in Jackson, MS were African American; African 
Americans were oversampled in Forsyth County to facilitate race-
specific analyses. This analysis included 11,656 participants from 
the fourth exam (1997–1999), which was considered the baseline 
for this study, when self-reported functional status was ascertained. 
Those with prevalent stroke at the time of the functional assessment 
(n  =  709) were excluded as patients with stroke may differ from 
those without stroke regarding risk associated with BP; partici-
pants who developed stroke after the index examination were not 
excluded. Another 683 were missing functional status data, leaving 
10,264 for the current analysis.
Functional Status and Disability Definitions
Functional status was assessed using standardized questionnaires 
to ascertain the level of difficulty (None, Some, A lot, and Unable) 
performing functional measures (26,27) and instrumental and basic 
activities of daily living adapted from validated questionnaires 
(26–29). Participants were asked how much difficulty they have per-
forming each of the following: walking room to room; transferring; 
dressing; feeding oneself; standing from a chair; walking ¼ mile; 
walking up 10 steps; stooping, crouching, kneeling; lifting or carry-
ing 10 pounds; doing housework; preparing meals; and managing 
money. Good function (GF) was assigned to participants reporting 
“No difficulty” on all questions and impaired function (IF) otherwise.
Mortality
ARIC mortality surveillance has been previously described and was 
completed through December 31, 2011 (25). All participants or their 
proxies are contacted annually by phone. Deaths were identified 
through records obtained from hospitals in the ARIC surveillance 
catchment areas, death certificates, and interviews of next of kin for 
potential out-of-hospital fatal events. Death certificates from state 
vital statistics offices were obtained on an ongoing basis. A question-
naire was also sent to participants’ physicians to confirm out-of-
hospital deaths.
BP Measurements
The average of the second and third measurements of resting BP, 
assessed by standardized protocols with a random-zero sphygmoma-
nometer, was used for this analysis. SBP was analyzed as both a con-
tinuous and a categorical variable according to the American Heart 
Association recommendations for normal (<120 mm Hg), pre-HTN 
(120–139 mmHg), and HTN (≥140 mm Hg) (30).
Covariates
Self-reported demographics, education, alcohol use, and smoking 
status were ascertained using standardized interviews. Medications 
were recorded at each study visit. Body mass index (kg/m2) was 
calculated from weight and height with participants wearing light-
weight clothes. Heart disease (31), stroke (32), and heart failure 
(33,34) were ascertained as previously described using self-report, 
medical records, and standardized questionnaires. Laboratory 
assays, including lipids, were obtained using standardized protocols; 
glucose was measured with the hexokinase method. Diabetes was 
defined as a fasting glucose level ≥126 mg/dl, a random glucose level 
≥200 mg/dl, or current use of hypoglycemic medications. A diagnosis 
of HTN (for descriptive purposes) was defined as use of antihyper-
tensive medications, SBP ≥140 or diastolic BP ≥90.
Statistical Analysis
Descriptive statistics were examined using Student’s t tests and 
Pearson’s chi-squared tests for continuous and categorical variables, 
respectively. Cox proportional hazard models with three-way inter-
actions between functional status, SBP, and age (p < .001 for triple 
interaction with continuous SBP) were used along with all lower-
level two-way interactions; the results were more conservative com-
pared with those from models using two-way interactions alone. 
The assumption of proportionality was examined visually with 
log-log-survival plots and supported using Schoenfeld residual tests. 
Sensitivity analyses were performed using Weibull distribution accel-
erated failure time models which generated the same conclusions. 
Kaplan–Meier plots were constructed to show cumulative incidence 
curves. Hazard ratios (HRs) for continuous SBP were modeled using 
flexible parametric restricted cubic-spline survival models (35). 
Models were adjusted for race, sex, body mass index, smoking, dia-
betes, heart disease, heart failure, statin use, antihypertensive medi-
cations, and race-clustering by site was accounted for using Huber 
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White sandwich estimators. Similar results were found with simple 
race- and sex-adjusted models. Sex- and race-stratified analyses were 
examined, and moderating effects were not supported (p value for 
all interactions > .15). All analyses were performed with Stata v13.1 
(StataCorp, College Station, TX).
Results
Table  1 shows characteristics of younger (<65  years) and older 
(≥65 years) participants stratified by Visit 4 functional status. The 
mean follow-up was 12.9 years. In both younger and older partici-
pants, IF was associated with older age, African American race, gen-
erally poorer health measures, and death. IF was associated with 
higher SBP, more so in younger than older participants, whereas IF 
was associated with lower diastolic BP in older participants. Figure 1 
shows unadjusted, cumulative mortality incidence for the normo-
tensive, pre-HTN, and HTN groups by age–functional status; crude 
HRs were similar to adjusted HRs. Mortality risk was higher in the 
older and IF groups.
Participants With Good Functional Status
Table  2 shows the adjusted risk of death associated with BP cat-
egories comparing across the same age and functional groups, using 
normal SBP (<120 mm Hg) as the reference. Among participants 
with GF, pre-HTN was associated with a 48% increase in mortality 
risk in younger persons, HR = 1.48 (95% confidence interval: 1.03, 
2.15) p = .036, and a 21% increase in mortality risk in older persons, 
HR = 1.21 (1.06, 1.37) p = .005. GF younger participants with HTN 
(SBP ≥ 140)  showed a doubling of mortality risk compared with 
normal SBP in younger persons, HR = 1.97 (1.29, 3.03) p = .002, 
and a 50% increase in mortality risk in older persons, HR = 1.47 
(1.36, 1.59) p < .001, showing some attenuation of, but still statisti-
cally and clinically meaningful, increased mortality risk among the 
older participants. Despite attenuation of risk associated with higher 
BP in the older groups, differences in absolute risks associated with 
higher SBP were comparable for those with GF. For example, the 
absolute risk among the younger GF group with HTN versus normal 
SBP was 18% versus 9% (absolute risk difference 9%); for the older 
group with GF, risk among those with HTN versus normal SBP was 
37% and 27%, respectively, an absolute risk difference of 10%.
Participants With Impaired Functional Status
Among those with IF, pre-HTN was not associated with mortality 
in younger participants, HR = 0.99 (0.85, 1.15) p  =  .93, and was 
protective in older participants, HR  =  0.87 (0.85, 0.90) p < .001. 
HTN remained associated with mortality in younger IF participants, 
HR = 1.54 (1.30, 1.82) p < .001, but was not associated with mortal-
ity in older IF participants, HR = 0.99 (0.87, 1.14) p = .93. Notably, 
the confidence intervals for older IF participants did not overlap with 
confidence intervals for older GF participants, supporting differences 
in associations of HTN with mortality between the older IF and the 
older GF groups. Differences in absolute risks associated with HTN 
for younger IF participants were similar to differences observed in the 
GF groups but not among older participants with IF. The absolute risk 
among the younger IF group with HTN versus normal SBP was 26% 
and 16%, respectively (absolute risk difference 10%). Conversely, for 
the older group with IF, risk for those with HTN versus normal SBP 
was 44% and 41%, respectively, an absolute risk difference of 3%. 
Table 1. Population Characteristics at the Baseline Functional Assessment (ARIC Visit 4) by Age and Functional Status
Variable
Age < 65 Years Age ≥ 65 Years
Good Function 
(N = 3,332)
Impaired function 
(N = 3,017)
p Value Good Function 
(N = 1,636)
Impaired Function 
(N = 2,279)
p Value
Age, mean (SD) 58.7 (3.2) 59.0 (3) <.001 68.5 (3) 68.9 (3) <.001
Black, n (%) 588 (18) 864 (29) <.001 192 (12) 436 (19) <.001
Education, n (%)
 <12 Years 333 (10) 547 (18) <.001 319 (20) 559 (25) <.001
 12 Years 1065 (32) 1127 (37) 529 (32) 742 (33)
 Some college 278 (8) 277 (9) 139 (9) 216 (9)
 ≥College degree 1650 (50) 1064 (35) 646 (40) 759 (33)
Male, n (%) 1657 (50) 970 (32) <.001 924 (56) 895 (39) <.001
Systolic BP, mmHg mean (SD) 122.7 (17) 126.0 (18) <.001 130.4 (19) 131.4 (19) .128
Diastolic BP, mmHg mean (SD) 72.1 (9.7) 72.1 (10) .934 69.6 (10) 68.6 (10) .002
Total cholesterol, mmol/L mean (SD) 5.18 (0.9) 5.24 (1.0) .012 5.19 (0.9) 5.20 (1.0) .657
HDL, mmol/L mean (SD) 1.31 (0.4) 1.30 (0.4) .222 1.28 (0.4) 1.28 (0.4) .930
LDL, mmol/L mean (SD) 3.17 (0.9) 3.19 (0.9) .251 3.20 (0.8) 3.16 (0.9) .172
Triglycerides, (mmol/L) mean (SD) 1.55 (0.9) 1.67 (1.0) <.001 1.59 (1.0) 1.68 (0.9) .004
BMI, kg/m2 mean (SD) 27.5 (4.6) 30.7 (6.4) <.001 26.9 (4.1) 29.2 (5.7) <.001
Current smoker n (%) 477 (14) 549 (18) <.001 160 (10) 269 (12) .046
Current alcohol use, n (%) 2031 (61) 1373 (46) <.001 843 (52) 945 (42) <.001
Hypertension, n (%) 1,126 (34) 1,444 (48) <.001 761 (47) 1,331 (59) <.001
Diabetes, n (%) 329 (10) 572 (19) <.001 228 (14) 436 (19) <.001
Heart disease, n (%) 154 (5) 208 (7) <.001 154 (10) 268 (12) .015
Heart failure, n (%) 22 (1) 77 (3) <.001 18 (1) 88 (4) <.001
Statins, n (%) 308 (9) 290 (10) .600 214 (13) 323 (14) .317
Hypertension meds, n (%) 822 (25) 1,160 (39) <.001 522 (32) 1,053 (47) <.001
Deaths, n (%) 365 (11) 519 (17) <.001 477 (29) 866 (38) <.001
Note: ARIC = Atherosclerosis Risk in Communities; BMI = body mass index; BP = blood pressure; HDL = high density lipoprotein; LDL = low density lipo-
protein.
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Thus, the absolute risk was higher in older persons and in those with 
IF. However, the absolute mortality increase attributed to HTN was 
similar and around 10% in younger participants, regardless of func-
tional status, and in older participants with GF, whereas the absolute 
difference was much lower (3%) and statistically nonsignificant in 
older participants with IF. Consistent results were found in sensitivity 
analyses including the 709 participants with prevalent strokes.
Figure 2 illustrates the estimated nonlinear relationships of con-
tinuous SBP with mortality by age and functional status. Median 
SBP values for each BP group were selected for displaying risk 
comparisons (SBP = 110 mmHg for those with SBP < 120 mmHg 
and SBP = 150 for those with SBP > 140 mmHg, vertical reference 
lines on plot). The x-axis shows continuous SBP along with distri-
butions of SBP for each age–function group. The HRs for each of 
these groups are shown on the y-axis comparing any given SBP in 
each age–function group with the reference of a younger GF par-
ticipant with SBP = 110 (HR = 1). For example, compared with a 
younger GF participant with SBP = 110 mmHg, an older GF par-
ticipant with the same SBP had 2.6 times the mortality risk, but 4.3 
times the risk for an older GF participant with SBP = 150 mmHg, 
indicating that the increase in risk for an older GF participant due 
to SBP was HR = 4.30/2.65 = 1.63 (95% confidence interval: 1.25, 
2.12). Older IF adults had higher mortality risks at lower SBP and 
experienced a statistically nonsignificant 5% risk increase for the 
same SBP increase; HR = 1.05 (95% confidence interval: 0.87, 1.29). 
Comparing older GF versus IF adults, the increase in SBP showed a 
35% lower effect on mortality risk for IF older adults; ratio of haz-
ard ratio = 0.65 (0.60, 0.69) p < .001. Similar but attenuated reduc-
tions in SBP effects were seen comparing younger GF versus younger 
IF adults; ratio of hazard ratio  =  0.82 (0.77, 0.86) p < .001. Of 
note, in older IF participants, we did not find support for increased 
mortality risk associated with HTN compared with normal SBP 
even when using a higher threshold of SBP = 160 mmHg, HR = 1.04 
(0.76, 1.43), although the sample size was smaller (N = 741).
Discussion
In this study of middle-aged and young-old adults, both age and 
impaired self-reported functional status attenuated the association 
of SBP to mortality. In older persons and in those with IF, for whom 
Figure 1. Kaplan–Meier (unadjusted) cumulative mortality incidence by systolic blood pressure group and hazard ratios for prehypertension (Pre-HTN: 120–
140 mmHg) and hypertension (HTN: ≥ 140 mmHg) compared with normal blood pressure (<120 mmHg) for the same age group and functional status.
Table 2. Adjusted Hazard Ratios Estimating Mortality Risk Associated With Pre-HTN and HTN Compared With Normal Blood Pressure in 
the Same Age and Functional Status Groups
Functional Group HTN Group
Younger Participants Older Participants
Deaths Hazard Ratio Deaths Hazard Ratio
Good function Normal 139/1,569 = 9% Reference 137/517 = 27% Reference
Pre-HTN 165/1,314 = 13% 1.48, p = .04 (1.03, 2.15) 217/710 = 31% 1.21, p = .005 (1.06, 1.37)
HTN 95/543 = 18% 1.97, p = .002 (1.29, 3.03) 190/517 = 37% 1.47, p < .001 (1.36, 1.59)
Impaired function Normal 199/1246 = 16% Reference 271/658 = 41% Reference
Pre-HTN 206/1,249 = 16% 0.99, p = .930 (0.85, 1.15) 402/1,066 = 38% 0.87, p < .001 (0.85, 0.90)
HTN 178/679 = 26% 1.54, p < .001 (1.30, 1.82) 358/809 = 44% 0.99, p = .930 (0.87, 1.14)
Notes: Models adjusted for race, sex, body mass index, smoking, diabetes, heart disease, heart failure, statin use, antihypertensive medications, and clustering 
by site.
HTN = Hypertension.
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the absolute mortality risk is high, the additional contribution of 
BP to mortality was much lower than in younger participants and 
in those with GF, although absolute risk differences were similar 
between older and younger persons with good functional status. The 
attenuation of risk associated with higher BP was especially evident 
both for those at older age and for those with IF. Clinicians could be 
misguided if using single BP targets for large segments of the popula-
tion. The findings in this study suggest that both age and functional 
status can inform clinicians of risk associated with BP and suggest 
that developing a personalized approach to BP management that 
incorporates measurable factors, of which age and functional status 
appear to be important, may be a rational strategy.
In older persons and in those with impaired functional status, the 
reduced contribution of BP to mortality risk could be due in part to 
a higher risk of death from other conditions, for example, cancer and 
hip fractures. HTN also causes endovascular dysfunction that has 
been linked with cerebral hypoperfusion (36); long-standing hypoper-
fusion of the brain or other end organs could contribute to cell death, 
organ dysfunction, and mortality, potentially explaining associations 
of lower BP with adverse outcomes. Recent studies also suggest that 
lower SBP is associated with higher mortality (37) and more cognitive 
decline (38) in selected older populations. These findings emphasize 
the need to elucidate mechanisms for the heterogeneity of responses to 
different BP levels, especially in older persons, and to develop a more 
personalized approach to BP management in older populations.
A large proportion (nearly half) of study participants were 
described as having IF using our broad definition. If a large segment 
of a population with impaired physical function indeed gains little to 
no benefit from BP control to guideline standards, this could have an 
immense population health impact. We caution, however, that we only 
considered mortality outcomes, and uncontrolled HTN contributes to 
other devastating outcomes including stroke. Further studies should 
examine the ways in which more precise assessments of functional 
status might better define appropriate BP levels for subgroups in 
whom risks and benefits related to BP differ in mid and late life.
The current study builds upon prior studies that reported 
increased mortality associated with higher SBP among high-func-
tioning adults aged 60  years or older but not among lower func-
tioning older adults (23,24) by extending findings to middle-aged 
persons. Based on the collective findings, we suggest that risk associ-
ated with higher BP should not be aggregated by age thresholds but 
that age, functional status, and related life expectancies should be 
considered. Failure to account for modifying characteristics under-
estimates risks for some, overestimates for others, and may explain 
disconcordance across studies of relationships between BP or BP 
treatment and mortality.
Impaired functional status is related to mortality and other 
adverse outcomes (21,22) and may identify persons in whom risks of 
interventions outweigh benefits. Conversely, well-functioning older 
persons may benefit from procedures or treatments, including more 
aggressive BP control, similar to younger persons. For example, a 
high-functioning 80-year-old man whose life expectancy is 10 years 
might benefit from maintaining a SBP near 130 mmHg rather than 
150 mmHg, but an 80-year-old man with IF whose life expectancy 
is 3 years might not live to see the benefit and may even have more 
adverse effects or potential harm. A growing literature cites the com-
plexity of treating the older population and the need to consider 
multiple chronic conditions, time to benefit, increasing susceptibil-
ity to adverse drug effects and risk of disease, quality of life, and 
patient preferences (39). These considerations are often presented in 
the context of avoiding unnecessary interventions and burdens on 
older, frail persons who may not benefit and could be harmed (39). 
The protective direction of the association between pre-HTN and 
mortality, compared with the current definition of normal BP, in our 
study supports this view. The converse argument is equally impor-
tant; high-functioning older adults with few clinical problems may 
achieve benefit from treatments similar to younger persons. Studies 
are needed to determine how functional assessments could inform 
clinicians of the most appropriate BP targets and how functional 
abilities might shift treatment targets across the life span.
Some limitations warrant discussion. Objective measures of 
functional status were not available and may be more sensitive 
than self-reported measures, particularly at higher levels of func-
tional abilities. However, self-reported measures are widely avail-
able, acceptable in clinical settings, and are validated measures of 
function (29,40). The age range of ARIC participants (52–75 years 
at the baseline functional assessment) limits the ability to examine 
relationships in the oldest old, that is, in those aged 80 and older, 
the subpopulation in which HTN treatment has been most contro-
versial. However, the current findings among middle-aged persons 
with IF add to the existing literature and should motivate further 
investigation in other populations. Potentially, among the oldest old 
with IF, higher BP targets may be beneficial although this remains 
to be defined. Additionally, the results could be useful in developing 
study designs and hypotheses to elucidate optimal treatment targets.
In summary, these findings emphasize the need to consider func-
tional markers of age in addition to chronologic age in estimating 
risk of BP in both middle-aged and older adults and underscore the 
relevance of simple, clinically feasible measures of function.
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